Tobramycin Inhalation Solution (TOBI) is a vital medication for controlling Pseudomonas aeruginosa infections in patients with cystic fibrosis (CF).
1. Dosage and Administration
1.1 Standard Dosage Regimen
(1) TOBI is for oral inhalation only. It must not be administered via subcutaneous, intravenous, or intrathecal injection.
(2) The recommended dose for adults and pediatric patients aged 6 years and older is one single-dose ampoule (300 mg) twice daily.
(3) Dosage is not adjusted for body weight; the same dose is used for all patients.
1.2 28-Day Intermittent Therapy
(1) TOBI follows a unique cyclic regimen: 28 days on treatment, followed by 28 days off treatment.
(2) After 28 consecutive days of therapy, discontinue TOBI for 28 days, then resume the next 28-day treatment cycle.
(3) Repeat this cycle continuously. Complete the full 28-day treatment period even if you feel better; do not stop early without medical advice.
1.3 Dosing Time and Missed Dose Management
(1) The two daily doses should be administered approximately 12 hours apart, and no less than 6 hours.
(2) If a dose is missed and more than 6 hours remain before the next scheduled dose, take the missed dose as soon as possible. If less than 6 hours remain, skip the missed dose and take the next dose at the regular time.
(3) Never double the dose to make up for a missed one.
1.4 Inhalation Technique
(1) Each administration takes approximately 15 minutes.
(2) The patient should be in a sitting or standing position and breathe normally through the mouthpiece.
(3) A nose clip may help ensure mouth breathing. Do not mix or dilute TOBI with dornase alfa or other medications in the nebulizer.
2. Precautions
2.1 Pre-Administration Inspection
(1) Inspect the solution for clarity before useFDA Access Data.
(2) The normal solution is pale yellow; do not use if it is cloudy or contains particulate matterFDA Access Data.
(3) Discard any product stored at room temperature for more than 28 days or past its expiration date.
2.2 Dosage Adjustment in Special Populations
(1) Pregnancy: Aminoglycosides can cause fetal harm. Use during pregnancy only after a thorough risk-benefit assessment.
(2) Lactation: Tobramycin is excreted in breast milk and may alter the infant's intestinal flora. Monitor the infant for diarrhea, bloody stools, or thrush.
(3) Pediatrics: Safety and efficacy in children under 6 years of age have not been established; use is not recommended.
(4) Elderly & Renal Impairment: Tobramycin is primarily excreted by the kidneys. Renal function monitoring is advised during treatment.
2.3 Drug Interaction Warnings
(1) Avoid Concomitant Use: Concurrent or sequential use with other neurotoxic, nephrotoxic, or ototoxic drugs (e.g., other aminoglycosides, vancomycin) should be avoided.
(2) Diuretics Contraindicated: Do not use with ethacrynic acid, furosemide, urea, or intravenous mannitol, as they may potentiate aminoglycoside toxicity.
(3) Systemic Aminoglycosides: If used concomitantly, monitor serum tobramycin concentrations and for toxic effects.
2.4 Adverse Reaction Monitoring
(1) Be alert for bronchospasm (wheezing, chest tightness), ototoxicity (tinnitus, hearing loss, vertigo), nephrotoxicity (elevated serum creatinine), and exacerbation of neuromuscular disorders during therapy.
(2) Seek immediate medical attention if any of these symptoms occur.
3. Healthy Lifestyle for Patients
3.1 Standardized Medication and Regular Follow-Up
(1) Strictly adhere to the 28-day on / 28-day off cycle; do not alter it arbitrarily. Regularly monitor lung function (FEV1), sputum culture and susceptibility, serum creatinine, and hearing.
(2) Inform your doctor if you carry mitochondrial DNA variants (e.g., m.1555A>G).
3.2 Respiratory Management
(1) Use airway clearance techniques before and after inhalation therapy to facilitate sputum expectoration.
(2) If using multiple inhaled medications, administer other drugs before TOBI (or as directed by your physician).
(3) When cough or sputum production increases, distinguish between worsening infection and a drug reaction.
